23-O-Acetylalisol B Antiviral Composition for SARS-CoV-2

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for COVID-19, including vaccinations and antiviral drugs like Paxlovid, are insufficient in addressing the high transmissibility and mutation of SARS-CoV-2 variants, leading to ongoing pandemic challenges and a need for novel therapeutic options.

Innovation Solution

The development of 23-O-Acetylalisol B, a triterpenoid compound isolated from Rhizoma alismatis, which exhibits antiviral, anti-inflammatory, and immunomodulatory properties, effectively reducing CoV replication and mutation, and potentially treating severe acute respiratory syndrome and autoimmune disorders.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current antiviral drugs like Paxlovid are used, then antiviral activity is achieved, but viral rebound incidence increases and drug resistance develops

Engineering Contradiction:

Improveantiviral activityVSAvoidviral rebound and drug resistance

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent employs a multi-component pharmaceutical composition comprising 23-O-acetylalisol B, aliskiren, and irbesartan that work synergistically to treat COVID-19. This combination approach acts as an intermediary strategy to overcome single-drug limitations, reducing viral rebound and resistance while maintaining antiviral efficacy through coordinated action of multiple agents with different mechanisms.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Speed

If SARS-CoV-2 variants with high transmissibility emerge, then spread capacity increases, but treatment effectiveness decreases

Engineering Contradiction:

ImprovetransmissibilityVSAvoidtreatment effectiveness

Core Design Contradiction:

SpeedVSReliability

Solution Approach 1:

The pharmaceutical composition is designed with multi-functional components that address various aspects of COVID-19 pathogenesis simultaneously. 23-O-acetylalisol B provides antiviral and anti-inflammatory effects, aliskiren addresses renin-angiotensin system dysregulation, and irbesartan provides additional anti-inflammatory and immunomodulatory effects. This universal approach maintains treatment effectiveness across different variants by targeting conserved pathological mechanisms.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent utilizes parameter changes in the pharmaceutical composition, specifically the synergistic interaction between multiple compounds at optimized dosages. The combination creates a therapeutic effect greater than the sum of individual components, adapting to variant mutations by maintaining effective concentration ranges that overcome reduced susceptibility while minimizing adverse effects.

Inventive Principle:

Principle #35Parameter changes

3Ease of operation

If single-component antiviral treatments are used, then treatment simplicity is maintained, but therapeutic efficacy is insufficient

Engineering Contradiction:

Improvetreatment simplicityVSAvoidtherapeutic efficacy

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent merges three distinct pharmacological agents into a single pharmaceutical composition that can be administered together. This combining strategy integrates antiviral, anti-inflammatory, and immunomodulatory functions into one treatment regimen, achieving superior therapeutic efficacy while maintaining operational simplicity through unified administration of the multi-component formulation.

Inventive Principle:

Principle #5Merging (Combining)

Data Source

PatentUS20230107428A123-o-acetylalisol b as a novel therapeutic agent for coronavirus induced severe acute respiratory syndrome

Publication Date: 2023.04.06 THE UNIVERSITY OF HONG KONG

AI summary

The subject invention pertains to a potent therapeutic agent, 23-O-Acetylalisol B, as an antiviral drug to treat COVID-19. 23-O-Acetylalisol B can broadly and dose-dependently inhibit coronavirus (CoVs), including MERS-CoV, SARS-CoV-2, SARS-CoV-2 Alpha and Delta variants. 23-O-Acetylalisol B has anti-inflammation and immunomodulation effects and has therapeutic effects to significantly ameliorate the CoV infection-induced lung damage.